Valuation : Cerus Corporation

Market Cap 534M 460M 431M 394M 742M 51.04B 744M 5.12B 2B 25.76B 2.01B 1.96B 85.43B P/E 2026 *
-75.7x
P/E 2027 * -265x
Enterprise Value 539M 464M 436M 398M 749M 51.52B 751M 5.17B 2.02B 26.01B 2.02B 1.98B 86.23B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.92x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day-2.57%
1 week-5.69%
Current month+23.26%
1 month-9.25%
3 months-9.25%
6 months+3.52%
Current year+28.64%
1 week 2.63
Extreme 2.63
2.82
1 month 2.06
Extreme 2.06
3.08
Current year 1.62
Extreme 1.62
3.47
1 year 1.17
Extreme 1.17
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap.
17/8/26 Sell

General Counsel

-30,000 0.0150%
16/7/26 Sell

Chief Executive Officer

-16,666 0.0083%
1/7/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
-2.57%-5.69%+102.29%+44.81% 534M
+2.66%+0.38%-15.14%+18.82% 127B
-0.93%-0.65%-22.84%+0.33% 12.12B
-1.12%-2.72%+86.28%+143.00% 10.6B
+0.28%+1.87%-50.57%-69.19% 4.22B
-0.42%+2.19%-16.73%+56.93% 2.72B
-1.70%-0.78% - - 2.04B
+1.02%-1.48%-32.82%-71.90% 1.78B
-0.45%-2.20%-17.93%-15.88% 1.62B
Average -0.36%-0.61%+4.07%+13.37% 18.05B
Weighted average by Cap. +1.91%+0.13%-9.81%+22.70%

Financials

2026 *2027 *
Net sales 249M 215M 201M 184M 346M 23.8B 347M 2.39B 931M 12.02B 935M 915M 39.84B 272M 234M 219M 200M 377M 25.95B 378M 2.6B 1.02B 13.1B 1.02B 997M 43.44B
Net income -8.77M -7.55M -7.08M -6.47M -12.18M -838M -12.22M -84.03M -32.79M -423M -32.91M -32.2M -1.4B -1.67M -1.44M -1.35M -1.23M -2.32M -159M -2.32M -15.98M -6.23M -80.41M -6.26M -6.12M -267M
Net Debt 5M 4.31M 4.04M 3.69M 6.95M 478M 6.97M 47.93M 18.7M 241M 18.77M 18.36M 800M -13M -11.2M -10.5M -9.59M -18.06M -1.24B -18.12M -125M -48.62M -627M -48.81M -47.75M -2.08B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
28/08/26 USD 2.650 -2.57% 1,683,565
27/08/26 USD 2.720 -0.73% 810,572
26/08/26 USD 2.740 +0.74% 1,103,083
25/08/26 USD 2.720 +1.12% 831,204
24/08/26 USD 2.690 -4.27% 1,623,599
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.650USD
Average target price
5.125USD
Spread / Average Target
+93.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock